Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 kinase inhibitors and myeloproliferative disorders

9 Feb 2010

Abstract excerpt

PURPOSE OF REVIEW: The pathophysiology of Philadelphia-chromosome negative myeloproliferative disorders has significantly advanced with the discovery of JAK2V617F. The prevalence of JAK2V617F mutation has made it a much anticipated target for inhibition; this review will update and assess progress. RECENT FINDINGS: Many agents have been studied in preclinical trials, of which few have entered clinical trials....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20087176
DOI: 10.1097/moh.0b013e3283366b91

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 kinase inhibitors and myeloproliferative disordersPMID 20087176Read ↗

New JAK2 inhibitors for myeloproliferative neoplasms.Semantic proximity Read ↗

Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome–Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

JAK2 inhibitors: are they the solution?Semantic proximity Read ↗

JAK2 inhibition for the treatment of hematologic and solid malignanciesSemantic proximity Read ↗

JAK2 inhibitors: what's the true therapeutic potential?Semantic proximity Read ↗

Kinase drug discovery approaches in chronic myeloproliferative disorders.Semantic proximity Read ↗

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Semantic proximity Read ↗

Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.Semantic proximity Read ↗

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.Semantic proximity Read ↗

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read ↗

Philadelphia Chromosome–Negative Myeloproliferative Disorders: Biology and TreatmentSemantic proximity Read ↗

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.